Aspira Pathlab & Diagnostics Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Aspira Pathlab & Diagnostics Ltd. on BSE

Load latest

Aspira Pathlab & Diagnostics Ltd.

27 May 2023

64.31

2.08%

Result

Aspira Pathlab & Diagnostics Ltd - 540788 - Financial Result For The Period Ended 31St March, …

BSE India

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), this is to inform that Board of Directors of the Company, in their meeting held today i.e. May 27, 2023 has inter-alia considered and approved the Audited Financial Results for the year ended on March 31, 2023. Please find attached: Audited Financial Results for the year ended on March 31, 2023 along with statement of Assets & Liabilities and Cash Flow Statement, Auditors'''' Report, and Declaration about unmodified opinion in audit report.

pdf

Aspira Pathlab & Diagnostics Ltd.

27 May 2023

64.31

2.08%

Board Meeting

Aspira Pathlab & Diagnostics Ltd - 540788 - Board Meeting Outcome for Outcome Of Board Meeting …

BSE India

Pursuant to Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''''Listing Regulations''''), the Board of Directors of the Company at their held on Saturday, 27th May, 2023 which was commenced at 03:30 P.M. and concluded at 05:20 PM. Attached Agenda items were approved in the meeting.

pdf

Aspira Pathlab & Diagnostics Ltd.

27 May 2023

64.31

2.08%

Annual Report

Annual report for Aspira Pathlab & Diagnostics Ltd. for FY-2023

None

pdf

Aspira Pathlab & Diagnostics Ltd.

20 May 2023

64.31

2.08%

Board Meeting

Aspira Pathlab & Diagnostics Ltd - 540788 - Board Meeting Intimation for Audited Financial Results For …

BSE India

Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2023 ,inter alia, to consider and approve Audited Financial Results for the quarter and financial year ended on March 31, 2023. This is to further inform that pursuant to the Company''''s Code of Conduct for Prohibition of Insider Trading, framed in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015; the trading window for all the Directors, Key Managerial Personnel, Designated persons and their immediate relatives shall remain closed and will re-open after 48 hours of the declaration of the financial results of the Company for the quarter and year ended 31st March, 2023.

pdf

Aspira Pathlab & Diagnostics Ltd.

26 Apr 2023

64.31

2.08%

Company Update

Aspira Pathlab & Diagnostics Ltd - 540788 - Non Applicability Of Statement Of Deviation(S) Or Variation(S) …

BSE India

Pursuant to Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular no. CIR/CFD/CMD1/162/2019 dated December 24, 2019 and with reference to email received from BSE dated 19.04.2023 with respect to Non-submission of Statement of Deviation(s) or Variation (s) for the quarter ended December 31, 2022 the Company hereby confirms, that there has been no deviation(s) or variation(s) in the use of the Proceeds raised through the Preferential Issues. Hence, the Statement of Deviation(s) or Variation(s) is not applicable to the Company.

pdf

Aspira Pathlab & Diagnostics Ltd.

22 Apr 2023

64.31

2.08%

Corp. Note

Aspira Pathlab & Diagnostics Ltd - 540788 - Format of the Annual Disclosure to be made …

BSE India

Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company Aspira Pathlab & Diagnostics Ltd 2 CIN NO. L85100MH1973PLC289209 3 Report filed for FY 2022-2023 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* 2022-2023, 2023-2024 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)2021-2022,2022-2023 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Priya PandeyDesignation :-Company Secretary and Compliance Officer Name of the Chief Financial Officer :- Balkrishna Talawadekar Designation : -Chief Financial Officer Date: 22/04/2023

pdf

Aspira Pathlab & Diagnostics Ltd.

14 Apr 2023

64.31

2.08%

Company Update

Aspira Pathlab & Diagnostics Ltd - 540788 - Certification Under Regulation 40(9) Read With Regulation 40(10) …

BSE India

Certification under Regulation 40(9) read with Regulation 40(10) of the SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended March 31, 2023

pdf

Aspira Pathlab & Diagnostics Ltd.

11 Apr 2023

64.31

2.08%

Corp. Note

Aspira Pathlab & Diagnostics Ltd - 540788 - Format of the Initial Disclosure to be made …

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyAspira Pathlab & Diagnostics Ltd 2CIN NO.L85100MH1973PLC289209 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Priya Pandey Designation: Company Secretary and Compliance Officer EmailId: priya.pandey@aspiradiagnostics.com Name of the Chief Financial Officer: Balkrishan Talawadekar Designation: Chief Financial Officer EmailId: balkrishna.talawadekar@aspiradiagnostics.com Date: 11/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

Aspira Pathlab & Diagnostics Ltd.

10 Apr 2023

64.31

2.08%

Company Update

Aspira Pathlab & Diagnostics Ltd - 540788 - Compliance Certificate Pursuant To Regulation 7(3) Of SEBI …

BSE India

Dear Sir/Madam, Pursuant to Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Compliance Certificate for the year ended March 31, 2023 duly signed by the Compliance Officer of the Company and the authorized representative of the Share Transfer Agent viz. M/s. Link Intime India Private Limited, certifying compliance with the requirements of Regulation 7(2) of the said Regulations. Kindly take the same on your record.

pdf

Aspira Pathlab & Diagnostics Ltd.

10 Apr 2023

64.31

2.08%

Company Update

Aspira Pathlab & Diagnostics Ltd - 540788 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) …

BSE India

Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018, for the quarter ended 31st March, 2023, as received from Link Intime India Pvt. Ltd, the Registrar and Share Transfer Agent (RTA) of the Company.

pdf

Is Aspira Pathlab & Diagnostics Ltd. worth buying?

4 Votes:

Buy 25.0%

Sell 50.0%

Hold 25.0%

39.77% Fall from 52W High

High vol. this week

Aspira Pathlab & Diagnostics Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Aspira Pathlab & Diagnostics Ltd. on BSE